Iovance Biotherapeutics, Inc.
IOVAHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeIovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic. With a market capitalization of $2.23B, it sits in mid-cap territory. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma.
Market Cap
$2.23B
Beta
0.69
P/E (TTM)
—
P/E (Fwd)
-15.67
EPS (TTM)
$-0.99
EPS (Fwd)
$-0.32
ROE
-47.5%
ROA
-23.6%
Cash
$313.4M
Total Debt
$47.8M
Free CF
-$149.1M
52W Change
124.2%
Annual Financials
Cash vs Debt
Iovance Biotherapeutics, Inc. holds $313.4M in cash against $47.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$149.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -47.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of 0.69 suggests IOVA is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IOVA.